| Current Price | $10.32 | Mkt Cap | $482.9M |
|---|---|---|---|
| Open | $9.78 | P/E Ratio | 0.00 |
| Prev. Close | $9.81 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $9.77 - $10.39 | Volume | 549,823 |
| 52-Wk Range | $8.45 - $18.22 | Avg. Daily Vol. | 524,843 |
| Current Price | $10.32 | Mkt Cap | $482.9M |
|---|---|---|---|
| Open | $9.78 | P/E Ratio | 0.00 |
| Prev. Close | $9.81 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $9.77 - $10.39 | Volume | 549,823 |
| 52-Wk Range | $8.45 - $18.22 | Avg. Daily Vol. | 524,843 |
The best Bull and Bear pitches based on recency and number of recommendations.
No stock better exemplifies the summer 2013 biopharma IPO bubble than Stemline. The stock peaked closed to 50 in October despite a lack of significant catalysts and has plunged along with the other 2013 IPO's. The current cap of 250M is much more… More
Since I wasn't following biopharma during the amazing 2001 bubble, I can say that I've never seen higher valuations. If you want to get a more objective idea of what;s been going on in the sector of late, check out the long-term chart for the biotech… More
Read the most recent pitches from players about STML.
Recs
steppenwolf2
(62.81)
Submitted: 3/24/2017 12:23:56 AM :
Start Price:
$8.50
NASDAQ:STML Score:
-12.98
Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel oncology therapeutics. Stemline is developing three clinical stage product candidates, SL-401, SL-801, and SL-701 that target Cancer Stem Cells (CSC). Researchers have identified Cancer Stem Cells (CSCs) as the highly malignant "seeds" of tumors, typically comprising 1-5% of the tumor, that give rise to the majority (95-99%) of other tumor cells known as the "tumor bulk".
While standard therapies, including chemotherapy and radiation, may initially shrink tumors by killing tumor bulk, the failure of these therapies to eradicate CSCs may be a major contributor to treatment failure, tumor relapse and poor survival.
Accordingly, the company believes that new therapies designed to target CSCs, in addition to tumor bulk, may represent a major advance in the fight against cancer. This premise has formed the basis of their drug development strategy.
Buy with a target price of $12 and a three year target of $25.
Recs
zzlangerhans
(99.72)
Submitted: 12/15/2013 10:57:02 AM :
Start Price:
$20.32
NASDAQ:STML Score:
-123.31
No stock better exemplifies the summer 2013 biopharma IPO bubble than Stemline. The stock peaked closed to 50 in October despite a lack of significant catalysts and has plunged along with the other 2013 IPO's. The current cap of 250M is much more attractive for a narrowly focused biopharma headed into pivotal trials of a largely unproven therapy for a potentially lucrative indication. Lock-up expiration activity is likely resolved and hedge fund transactions have lately been favorable. If the momentum reverses once the pivotal trials kick off in early 2014, I might tag a small chunk of speculative capital onto Stemline for the ride.
Find the members with the highest scoring picks in STML.
thebeef41 (41.42) Score: +163.50
The Score Leader is the player with the highest score across all their picks in STML.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| thebeef41 | 41.42 | 10/1/2013 |
|
3Y | $45.53 | -77.34% | +86.16% | +163.50 | 0 Comment | |
| KidJones | 34.06 | 8/13/2013 |
|
5Y | $35.75 | -71.15% | +86.28% | +157.43 | 0 Comment | |
| primetime300 | 98.51 | 11/18/2013 |
|
5Y | $21.99 | -53.09% | +74.58% | +127.67 | 0 Comment | |
| portefeuille | 98.38 | 3/8/2016 |
|
5Y | $5.24 | +96.85% | +58.15% | +38.69 | 0 Comment | |
| Bigcaps19 | 69.09 | 10/3/2019 |
|
5Y | $9.71 | +6.23% | +9.41% | +3.18 | 0 Comment | |
| stainsolution | < 20 | 12/4/2019 |
|
5Y | $10.24 | +0.73% | +2.11% | -1.38 | 0 Comment | |
| TheGreatSatan | 99.99 | 8/11/2017 |
|
5Y | $7.85 | +31.40% | +28.99% | -2.41 | 0 Comment | |
| steppenwolf2 | 62.81 | 3/24/2017 |
|
1Y | $8.50 | +21.35% | +34.33% | -12.98 | 1 Comment | |
| tenmiles | 30.15 | 6/23/2017 |
|
5Y | $9.05 | +13.98% | +29.41% | -15.43 | 0 Comment | |
| portefeuille4 | 99.55 | 9/2/2016 |
|
5Y | $8.05 | +28.14% | +44.37% | -16.23 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
